{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T05:21:55Z","timestamp":1675747315269},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Results from ALPINE, a phase III trial, indicate that the second-generation BTK inhibitor zanubrutinib is superior to ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Besides having a better safety profile, zanubrutinib also improved progression-free survival.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2022-0080","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T13:58:16Z","timestamp":1671199096000},"page":"252-252","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BTK Inhibitor Options Expand for CLL\/SLL"],"prefix":"10.1158","volume":"13","member":"1086","container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NB2022-0080\/711682\/BTK-Inhibitor-Options-Expand-for-CLL-SLLBTK","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/2\/252\/3266847\/252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/2\/252\/3266847\/252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T08:21:08Z","timestamp":1675671668000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/2\/252\/716293\/BTK-Inhibitor-Options-Expand-for-CLL-SLLBTK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2022-0080","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]}}}